GlobalData on MSN19h
EMA to review GSK’s Nucala for COPD treatment expansionGSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
Zacks Investment Research on MSN1d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPDGSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
The European Medicines Agency (EMA) gave its approval to an artificial intelligence diagnostic tool for the first time on ...
today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. The application seeks approval for the treatment of patients with ...
A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...
The European Medicines Agency provides an interactive map with data from the information system for clinical trials. This is ...
Driving Restrictions Beyond 1 Month After CAR-T Therapy Not Needed for All Patients, Researchers Say
Researchers proposed changing the recommendations for universal driving restrictions after CAR T-cell infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback